Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

DG DISPATCH - ICDT-HIV: Marinol (Dronabinol) May Reduce Nausea, Vomiting From HIV Therapy By David Jack, MD Special to DG News GLASGOW, SCOTLAND -- October 23, 2000 -- Nausea and vomiting are very common side effects that accompany much of the antiretroviral therapy used to treat human immunodeficiency virus (HIV) infection. The latest data presented at the 5th International Congress on Drug Therapy in HIV Infection (ICDT-HIV), in Glasgow, Scotland, show that many patients who add Marinol (dronabinol) to their antiretroviral therapy suffer significantly less nausea and vomiting. Dr. Roger Anderson, of Anderson Clinical Research, in Pittsburgh, Philadelphia, presented the results of this MAR 0698 study involving 41 patients on stable antiretroviral therapy. Patients were randomly assigned to either Marinol 2.5 mg twice daily within one hour of taking antiretroviral medication or Marinol 5.0 mg at bedtime for six weeks. Patients were assessed by means of a questionnaire at the study start and after six weeks. The questionnaire asked for information on the number of episodes of vomiting, the severity of nausea and duration of episodes when they felt unwell during the 48 hour period prior to assessment. A total of 27 patients were ultimately available for evaluation, 14 in the Marinol twice-daily group and 13 in the Marinol at bedtime group. None of the patients discontinuing the study did so for reasons of efficacy. A total of 93 percent (13/14) of those in the Marinol twice-daily group exhibited a greater than 50 percent improvement in their symptoms of nausea and vomiting and 77 percent (10/13) of those taking Marinol at bedtime had a greater than 50 percent improvement. The severity of the nausea improved by at least one grade in 96 percent (26/27) of patients and no "severe" or "very severe" nausea was reported in either group. Dr Anderson commented: "Based on these findings, Marinol may have a significant impact on managing antiretroviral-associated nausea and vomiting." Marinol was first introduced by Roxane Laboratories in 1986 for the treatment of nausea and vomiting which accompanies cancer chemotherapy. It is co-promoted by Unimed Pharmaceuticals Inc., a subsidiary of Solvay Pharmaceuticals Inc. Related Links: Marinol (dronabinol), Roxane Laboratories, Unimed Pharmaceuticals Inc and Solvay Pharmaceuticals Inc. E-mail this page to a friend or colleague! To print, use this version